Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anus Neoplasms | 2 | 2018 | 41 | 1.110 |
Why?
|
| Melanoma | 3 | 2017 | 898 | 0.780 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 744 | 0.750 |
Why?
|
| Pancreatectomy | 6 | 2025 | 144 | 0.610 |
Why?
|
| Sentinel Lymph Node | 1 | 2017 | 9 | 0.550 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 118 | 0.530 |
Why?
|
| Postoperative Complications | 6 | 2025 | 3066 | 0.480 |
Why?
|
| Lymph Nodes | 3 | 2017 | 373 | 0.460 |
Why?
|
| Preoperative Care | 2 | 2020 | 354 | 0.450 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 880 | 0.430 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2022 | 165 | 0.410 |
Why?
|
| Pancreatic Neoplasms | 4 | 2022 | 713 | 0.400 |
Why?
|
| Intraoperative Care | 2 | 2025 | 123 | 0.370 |
Why?
|
| Dactinomycin | 1 | 2011 | 48 | 0.370 |
Why?
|
| Melphalan | 1 | 2011 | 43 | 0.360 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 1284 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1302 | 0.280 |
Why?
|
| Gallbladder Neoplasms | 2 | 2018 | 14 | 0.280 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2019 | 377 | 0.270 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 424 | 0.270 |
Why?
|
| Tumor Burden | 2 | 2018 | 229 | 0.260 |
Why?
|
| Aged | 19 | 2025 | 20344 | 0.260 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2025 | 105 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1234 | 0.230 |
Why?
|
| Colonic Neoplasms | 2 | 2018 | 252 | 0.230 |
Why?
|
| Pancreatitis, Chronic | 1 | 2025 | 70 | 0.220 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 258 | 0.220 |
Why?
|
| Fluid Therapy | 1 | 2025 | 145 | 0.210 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 77 | 0.210 |
Why?
|
| Middle Aged | 17 | 2025 | 27697 | 0.210 |
Why?
|
| Retrospective Studies | 14 | 2025 | 17005 | 0.200 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 303 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2018 | 151 | 0.190 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2019 | 26 | 0.170 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 167 | 0.170 |
Why?
|
| Coloring Agents | 1 | 2020 | 68 | 0.160 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 39 | 0.160 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2020 | 31 | 0.160 |
Why?
|
| Resource Allocation | 1 | 2020 | 52 | 0.160 |
Why?
|
| Parathyroidectomy | 1 | 2020 | 51 | 0.160 |
Why?
|
| Indocyanine Green | 1 | 2020 | 53 | 0.160 |
Why?
|
| Male | 19 | 2025 | 62543 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 379 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 152 | 0.150 |
Why?
|
| Nutrition Assessment | 1 | 2020 | 124 | 0.150 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2004 | 370 | 0.150 |
Why?
|
| Thrombosis | 1 | 2004 | 502 | 0.150 |
Why?
|
| Ureter | 1 | 2020 | 95 | 0.150 |
Why?
|
| Humans | 24 | 2025 | 126753 | 0.150 |
Why?
|
| Survival Rate | 3 | 2018 | 2101 | 0.150 |
Why?
|
| Cholecystectomy | 1 | 2018 | 58 | 0.140 |
Why?
|
| Malnutrition | 1 | 2020 | 150 | 0.140 |
Why?
|
| Hernia, Abdominal | 1 | 2018 | 18 | 0.140 |
Why?
|
| Anal Canal | 1 | 2018 | 79 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2019 | 122 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 622 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 226 | 0.140 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 23 | 0.130 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 105 | 0.130 |
Why?
|
| Female | 17 | 2025 | 68330 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 6668 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 104 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 119 | 0.130 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 76 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.130 |
Why?
|
| Drainage | 1 | 2017 | 250 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 124 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 125 | 0.120 |
Why?
|
| Adult | 8 | 2025 | 30410 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 263 | 0.120 |
Why?
|
| Quality of Life | 1 | 2025 | 2029 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 227 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2019 | 12546 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.110 |
Why?
|
| Decision Making | 1 | 2020 | 664 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.110 |
Why?
|
| Hospitals | 1 | 2017 | 428 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 667 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 222 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2018 | 1193 | 0.100 |
Why?
|
| Length of Stay | 2 | 2025 | 1377 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2018 | 516 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1135 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 44 | 0.090 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2011 | 13 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 86 | 0.090 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2011 | 67 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 138 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 973 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 730 | 0.080 |
Why?
|
| Young Adult | 4 | 2019 | 9665 | 0.070 |
Why?
|
| Pancreatic Fistula | 1 | 2008 | 28 | 0.070 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 36 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2011 | 933 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2507 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 4954 | 0.060 |
Why?
|
| Propensity Score | 1 | 2025 | 250 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2017 | 1495 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1364 | 0.050 |
Why?
|
| Posture | 1 | 2004 | 132 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 1493 | 0.050 |
Why?
|
| Proteins | 1 | 2008 | 1018 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 2582 | 0.040 |
Why?
|
| Parathyroid Hormone | 1 | 2020 | 77 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 3586 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1758 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5114 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2020 | 299 | 0.040 |
Why?
|
| Fascia | 1 | 2018 | 14 | 0.040 |
Why?
|
| Colon, Ascending | 1 | 2018 | 8 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 12 | 0.040 |
Why?
|
| Neomycin | 1 | 2018 | 36 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 3251 | 0.030 |
Why?
|
| Cathartics | 1 | 2018 | 29 | 0.030 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 34 | 0.030 |
Why?
|
| Citric Acid | 1 | 2018 | 40 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 109 | 0.030 |
Why?
|
| Metronidazole | 1 | 2018 | 157 | 0.030 |
Why?
|
| Operative Time | 1 | 2018 | 193 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 261 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 192 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 692 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 669 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1047 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 634 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 898 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1137 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1374 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1220 | 0.030 |
Why?
|
| United States | 2 | 2020 | 11310 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 39 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 684 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1536 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 20002 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 4772 | 0.020 |
Why?
|
| Pancreaticojejunostomy | 1 | 2008 | 6 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6134 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6214 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 2789 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 10555 | 0.010 |
Why?
|